Skip to main content
Equibles
VVOS logo

VVOS · Vivos Therapeutics, Inc. · Metrics

Track VVOS — free

Use VVOS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VVOS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.18 +0.01 (+6.70%) At close · Sep 10
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, we had approximately $1.8 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next twelve months from the date of the issuance of these financial statements. Without additional financing, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$3.42M
Shares
20.12M

VVOS metrics

63 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.18
Market cap
$3.42M

Price action

20 metrics
Price change (1W)
-1.4%
Price change (30D)
-45.9%
Price change (3M)
-73.4%
Price change (6M)
-87.3%
Price change (YTD)
-91.6%
Price change (1Y)
-95.6%
Trailing year
Price change (5Y)
—
52-week high
$3.87
52-week low
$0.17
Change from 52-week high
-95.6%
Change from 52-week low
+0.9%
Annualized volatility
94.5%
Annualized volatility (3M)
114.5%
Beta
1.1
RSI (14D)
27.3
Price vs SMA 50
-50.8%
Price vs SMA 200
-84.7%
Avg volume (3M)
11.47M
Relative volume
4.0
Average dollar volume
$2.53M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
20.12M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.5×
reciprocal yield 213.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 610.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-743.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.4×
reciprocal yield 72.6%
EV / revenue historical average (5Y)
1.5×
reciprocal yield 68.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-15

Profitability

9 metrics
Gross margin
61.9%
Operating margin
-107.9%
Trailing 12 months
Net margin
-121.8%
Gross profit (TTM)
$12.94M
Operating profit (TTM)
−$22.55M
Net income (TTM)
−$25.46M
Trailing 12 months
Diluted EPS (TTM)
$-1.90
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.16

Growth

11 metrics
Revenue growth YoY
+34.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$20.90M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+94.6%
Year over year · more shares
Revenue CAGR (3Y)
+2.9%
Revenue CAGR (5Y)
+5.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-105.4%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$20.76M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$6.36M
Latest balance sheet
Cash & equivalents
$1.77M
Total assets
$24.14M
Total debt
$8.14M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$17.13M
Capital expenditures (TTM)
$1.88M
R&D (TTM)
$100,000
SG&A (TTM)
—
Stock compensation (TTM)
$303,000
R&D / revenue
—
Stock compensation / revenue
1.4%

Ownership (13F)

3 metrics
13F filers
22
13F filer change QoQ
-2
Institutional ownership
2.6%

Short interest

3 metrics
Short interest
12.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1716166 CUSIP 92859E207 13F (30d) 11 filings 11 filers Visit website Investor relations